NMRA

Latest SEC Filings & News for NMRA

3 most recent filings and news items mentioning NMRA. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/NMRA/news?limit=20"

Pull NMRA filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
RegulatoryJul 27, 2026Neutral

Neumora reports favorable NMRA-215 toxicology results

Neumora Therapeutics reported positive preclinical toxicology data for its NLRP3 inhibitor NMRA-215. The results support the advancement of the drug candidate to the clinic. The company plans to file its IND in late 2026.

View filing at SEC.gov →
NewsJun 16, 2026Neutral

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

View filing at SEC.gov →
RegulatoryJun 15, 2026Negative

Neumora discontinues navacaprant after Phase 3 failures in depression

Neumora's Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to meet primary endpoints for major depressive disorder, prompting the company to halt development. The company is implementing a 35% workforce reduction and refocusing on three pipeline programs with cash runway th

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.